Literature DB >> 7734295

Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

P Hietanen1, C Blomqvist, V M Wasenius, E Niskanen, K Franssila, S Nordling.   

Abstract

The relationship between the response to chemotherapy with cyclophosphamide, epirubicin and fluorouracil as well as the time to progression of metastasised breast cancer and DNA ploidy and S-phase fraction (SPF) of primary tumours was examined using paraffin-embedded tumour tissue from 81 patients. The response to chemotherapy was significantly better in patients with tumours with a high SPF, and in addition the time to progression was longer in the high-SPF group. There was no significant difference when the DNA ploidy and response to treatment were compared.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7734295      PMCID： PMC2033766          DOI： 10.1038/bjc.1995.198

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  25 in total

1.  Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle.

Authors:  H Baisch; W Göhde; W A Linden
Journal:  Radiat Environ Biophys       Date:  1975-06-13       Impact factor: 1.925

2.  Tritiated thymidine labeling index and response in human breast cancer.

Authors:  A Sulkes; R B Livingston; W K Murphy
Journal:  J Natl Cancer Inst       Date:  1979-03       Impact factor: 13.506

3.  Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cytomorphologic changes, initial tumor ploidy, and tumor regression.

Authors:  M Briffod; F Spyratos; M Tubiana-Hulin; C Pallud; C Mayras; A Filleul; J Rouëssé
Journal:  Cancer       Date:  1989-02-15       Impact factor: 6.860

4.  Association of DNA index and S-phase fraction with prognosis of nodes positive early breast cancer.

Authors:  D W Hedley; C A Rugg; R D Gelber
Journal:  Cancer Res       Date:  1987-09-01       Impact factor: 12.701

5.  Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry.

Authors:  D W Hedley; M L Friedlander; I W Taylor; C A Rugg; E A Musgrove
Journal:  J Histochem Cytochem       Date:  1983-11       Impact factor: 2.479

6.  Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer.

Authors:  O P Kallioniemi; T Hietanen; J Mattila; M Lehtinen; K Lauslahti; T Koivula
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

7.  Improving the prognostic value of DNA flow cytometry in breast cancer by combining DNA index and S-phase fraction. A proposed classification of DNA histograms in breast cancer.

Authors:  O P Kallioniemi; G Blanco; M Alavaikko; T Hietanen; J Mattila; K Lauslahti; M Lehtinen; T Koivula
Journal:  Cancer       Date:  1988-11-15       Impact factor: 6.860

8.  Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates.

Authors:  Y Remvikos; M Jouve; P Beuzeboc; P Viehl; H Magdelenat; P Pouillart
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

9.  Differential killing efficacy of twenty antitumor drugs on proliferating and nonproliferating human tumor cells.

Authors:  B Drewinko; M Patchen; L Y Yang; B Barlogie
Journal:  Cancer Res       Date:  1981-06       Impact factor: 12.701

10.  Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer.

Authors:  J R Masters; R S Camplejohn; R R Millis; R D Rubens
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640
View more
  11 in total

Review 1.  Prognosis and prediction of response in breast cancer: the current role of the main biological markers.

Authors:  A Ravaioli; L Bagli; A Zucchini; F Monti
Journal:  Cell Prolif       Date:  1998 Jun-Aug       Impact factor: 6.831

2.  Identification of hypermethylated genes associated with cisplatin resistance in human cancers.

Authors:  Xiaofei Chang; Constance L Monitto; Semra Demokan; Myoung Sook Kim; Steven S Chang; Xiaoli Zhong; Joseph A Califano; David Sidransky
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

3.  Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer.

Authors:  T A Järvinen; J Kononen; M Pelto-Huikko; J Isola
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

4.  Reliability of cyclin A assessment on tissue microarrays in breast cancer compared to conventional histological slides.

Authors:  K Aaltonen; C Ahlin; R-M Amini; L Salonen; M-L Fjällskog; P Heikkilä; H Nevanlinna; C Blomqvist
Journal:  Br J Cancer       Date:  2006-06-05       Impact factor: 7.640

5.  Increased doxorubicin uptake and toxicity in multicellular tumour spheroids treated with DC electrical fields.

Authors:  H Sauer; V Pütz; K Fischer; J Hescheler; M Wartenberg
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

6.  A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients.

Authors:  R L Huuhtanen; T A Wiklund; C P Blomqvist; T O Böhling; M J Virolainen; B Tribukait; L C Andersson
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

7.  A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs.

Authors:  H R Mellor; D J P Ferguson; R Callaghan
Journal:  Br J Cancer       Date:  2005-08-08       Impact factor: 7.640

8.  The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.

Authors:  Carina Strand; Martin Bak; Signe Borgquist; Gunilla Chebil; Anna-Karin Falck; Marie-Louise Fjällskog; Dorthe Grabau; Ingrid Hedenfalk; Karin Jirström; Marie Klintman; Per Malmström; Hans Olsson; Lisa Rydén; Olle Stål; Pär-Ola Bendahl; Mårten Fernö
Journal:  Springerplus       Date:  2013-03-14

9.  Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

Authors:  T A Järvinen; K Holli; T Kuukasjärvi; J J Isola
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer.

Authors:  J Sjöström; S Krajewski; K Franssila; E Niskanen; V M Wasenius; S Nordling; J C Reed; C Blomqvist
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.